Overview

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters
Details
Lead Sponsor:
Amgen
Treatments:
Cinacalcet
Cinacalcet Hydrochloride